BioAge Labs advances pipeline with new collaborations and development candidates Biotech focuses on next-gen APJ agonists and NLRP3 inhibitors; and partners with Lilly to address aging targets. Kristen Fortney #biotech
Longevity.Technology’s Post
More Relevant Posts
-
Exciting News! We are thrilled to announce that iQ Biosciences now offers Bioconjugation Services for ADCs (Antibody-Drug Conjugates)! https://bit.ly/4izf7gt Our new bioconjugation capabilities are designed to support the development of cutting-edge ADCs by providing: ✅ High-quality bioconjugation tailored to your needs ✅ Analytical services to ensure your ADC's quality, stability, and efficacy ✅ Seamless integration with our in vitro assays like target binding validation, ADC internalization, effector function evaluation, direct cytotoxicity, and bystander effect assessment. Whether you're in discovery, preclinical development, or early-stage research, our comprehensive bioconjugation services aim to accelerate your ADC pipeline with efficiency and precision. Let's build the future of targeted therapies together! 🚀 #Bioconjugation #ADC #AntibodyDrugConjugates #CRO #InVitroServices #DrugDevelopment #iQBiosciences
-
Have a #peptide as a lead candidate? Great: we can optimize it for you! Need to find a peptide for your challenging target? Perfect: our #display libraries can be used to identify high affinity peptide leads for further development! Watch how our integrated platform at #IRBM can help accelerate your peptide discovery journey. #IRBM #PeptideDiscovery #DrugDiscovery #Peptides #Therapeutics
Peptide therapeutics are opening new doors in drug discovery, and at IRBM, we're integrating decades of expertise to bring your peptide projects to life—from initial concept to optimized candidate. Watch how our collaborative approach and advanced technologies can help accelerate your peptide discovery journey. ~~~ 🔬 We’re IRBM, an Italian-based CRO partner specializing in early-stage drug discovery. All our work takes place at a single research site, enabling seamless collaboration to support preclinical research across various therapeutic areas. ➕ Follow us for practical insights into advancing drug discovery, updates on our capabilities, and the latest trends in preclinical innovation. #IRBM #PeptideDiscovery #DrugDiscovery #Peptides #Therapeutics
-
Thrilled to share that iQ Biosciences has launched Bioconjugation Services for ADCs! Our team is ready to support ADC development with high-quality conjugation, comprehensive analytics, and integrated in vitro assays. Exciting times ahead for targeted therapies! 🚀 #Bioconjugation #ADC #DrugDevelopment #CRO"
Exciting News! We are thrilled to announce that iQ Biosciences now offers Bioconjugation Services for ADCs (Antibody-Drug Conjugates)! https://bit.ly/4izf7gt Our new bioconjugation capabilities are designed to support the development of cutting-edge ADCs by providing: ✅ High-quality bioconjugation tailored to your needs ✅ Analytical services to ensure your ADC's quality, stability, and efficacy ✅ Seamless integration with our in vitro assays like target binding validation, ADC internalization, effector function evaluation, direct cytotoxicity, and bystander effect assessment. Whether you're in discovery, preclinical development, or early-stage research, our comprehensive bioconjugation services aim to accelerate your ADC pipeline with efficiency and precision. Let's build the future of targeted therapies together! 🚀 #Bioconjugation #ADC #AntibodyDrugConjugates #CRO #InVitroServices #DrugDevelopment #iQBiosciences
-
🔬 𝐏𝐡𝐚𝐫𝐦𝐚 𝐂𝐨𝐧𝐜𝐥𝐚𝐯𝐞 𝐬𝐞𝐫𝐢𝐞𝐬 𝟐𝟎𝟐𝟒: 𝐓𝐡𝐞 𝐏𝐡𝐚𝐫𝐦𝐚 𝐜𝐨𝐧𝐧𝐞𝐜𝐭𝐢𝐨𝐧, WITH SCIEX Join us for a high-level virtual event connecting every pharmaceutical development stage, from #discovery to QA/QC. 📅 Date: October 23-24, 2024 🕒 Time: 10:00 AM - 12:00 PM CET ❗ 𝐑𝐞𝐠𝐢𝐬𝐭𝐞𝐫 𝐡𝐞𝐫𝐞: https://lnkd.in/dHVs97Xg Our Lab Manager, Jose Carlos Gonzalez, will talk about 'Sphingolipid biomarkers in neurodegenerative drug development,' offering insights from the lab’s perspective, where crucial analyses are performed to support the development of these targeted therapies. Moreover, industry leaders such as representatives from AstraZeneca, NUVISAN The Science CRO, biocrates life sciences ag, Cyprotex, Expert Partners - Mérieux NutriSciences Italia, Scantox Group, ERBC, KCAS Bio, Univerza v Mariboru, will delve into the intricate process of bringing new treatments to patients. Don't miss this opportunity to connect with pharmaceutical #innovation! #SphingolipidBiomarkers #Biomarkers #Neurodegenerative #DrugDevelopment #Parkinson #Alzheimer #Sclerosis #Metabolomics #PharmaConclave2024 #PharmaceuticalInnovation #Pharma #Biopharma #PhmarceuticalIndustry #DrugDiscovery #Proteomics #Adme #dmpk #Chromatography #CRO #Laboratory
-
It was thrilling to be a part of this video, even if it was just for a few seconds! It was an experience that made me smile😊 🔎SPR is an indispensable tool for high-throughput screening of peptide libraries, allowing us to rapidly identify the most promising compounds. #peptidechemistry #irbm #biophysics #SPR
Peptide therapeutics are opening new doors in drug discovery, and at IRBM, we're integrating decades of expertise to bring your peptide projects to life—from initial concept to optimized candidate. Watch how our collaborative approach and advanced technologies can help accelerate your peptide discovery journey. ~~~ 🔬 We’re IRBM, an Italian-based CRO partner specializing in early-stage drug discovery. All our work takes place at a single research site, enabling seamless collaboration to support preclinical research across various therapeutic areas. ➕ Follow us for practical insights into advancing drug discovery, updates on our capabilities, and the latest trends in preclinical innovation. #IRBM #PeptideDiscovery #DrugDiscovery #Peptides #Therapeutics
-
📢 Our First #BioLens is out! 🔔 This is a weekly roundup of news in the biotechnology, pharmaceutical, and diagnostics sectors! 🔎 Let's see what we have selected for the first BioLens: 🟦 Daiichi Sankyo Acquires Glycotope's Solid Tumor ADC for $132.5M ↳ https://lnkd.in/dDnqnszy 🟩 Tune Therapeutics Secures $175M to Advance Epigenetic Therapy for Hepatitis B ↳ https://lnkd.in/ehg4DcuW 🟪 Lonza and Iconovo AB Collaborate on Intranasal Biologic for Obesity Treatment ↳ https://lnkd.in/dc6-EnG8 🟨 Johnson & Johnson Pauses U.S. Rollout of Varipulse Heart Device Following Stroke Reports ↳ https://lnkd.in/dsVKKj7q 🟥 CARB-X Awards Melio $3.5M to Develop Rapid Neonatal Sepsis Test ↳ https://lnkd.in/ddRX3Bcd #Biotechnology #Pharma #biopharma #diagnostics #medicaldevice #IVD
-
Peptide therapeutics are opening new doors in drug discovery, and at IRBM, we're integrating decades of expertise to bring your peptide projects to life—from initial concept to optimized candidate. Watch how our collaborative approach and advanced technologies can help accelerate your peptide discovery journey. ~~~ 🔬 We’re IRBM, an Italian-based CRO partner specializing in early-stage drug discovery. All our work takes place at a single research site, enabling seamless collaboration to support preclinical research across various therapeutic areas. ➕ Follow us for practical insights into advancing drug discovery, updates on our capabilities, and the latest trends in preclinical innovation. #IRBM #PeptideDiscovery #DrugDiscovery #Peptides #Therapeutics
-
iPSC Market Leaders and their Business Models - https://lnkd.in/dkU6JngW Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug discovery and development, toxicology screening, disease modelling, personalized medicine, cell-based therapeutics, and beyond. A fascinatingly diverse range of business models have been developed by market competitors to provide iPSC specific products, services, technologies, and therapies across the life science sector. iPSC market leaders by product type are the following: FUJIFILM Cellular Dynamics, Inc CDI, Ncardia, Axol Bioscience Ltd., REPROCELL, R&D Systems, Promega Corporation , Miltenyi Biotec, STEMCELL Technologies, Takara Bio Inc., Thermo Fisher Scientific, iXCells Biotechnologies, DefiniGEN, Evotec, TreeFrog Therapeutics, Catalent Pharma Solutions, Bristol Myers Squibb, Cynata Therapeutics, Century Therapeutics, Inc, and BlueRock Therapeutics. Read more at: https://lnkd.in/dkU6JngW #ipsc #stemcell #ipscells
-
-
Founder of BioInformant.com, World's Largest Publisher of Stem Cell Industry News | Investor | Former USA Rugby Player 🏉
iPSC Market Leaders and their Business Models - https://lnkd.in/e5WM_CSQ Today, induced pluripotent stem cells (iPSCs) are being exploited for uses in drug discovery and development, toxicology screening, disease modelling, personalized medicine, cell-based therapeutics, and beyond. A fascinatingly diverse range of business models have been developed by market competitors to provide iPSC specific products, services, technologies, and therapies across the life science sector. iPSC market leaders by product type are the following: FUJIFILM Cellular Dynamics, Inc CDI, Ncardia, Axol Bioscience Ltd., REPROCELL, R&D Systems, Promega Corporation , Miltenyi Biotec, STEMCELL Technologies, Takara Bio Inc., Thermo Fisher Scientific, iXCells Biotechnologies, DefiniGEN, Evotec, TreeFrog Therapeutics, Catalent Pharma Solutions, Bristol Myers Squibb, Cynata Therapeutics, Century Therapeutics, Inc, and BlueRock Therapeutics. Read more at: https://lnkd.in/e5WM_CSQ #ipsc #stemcell #ipscells
-
-
Our update this morning, covered at Benzinga - Enveric Biosciences, Inc. Advances #NonHallucinogenic DMT Analog Drug With Promising Preclinical Results https://lnkd.in/e_YAn2eB
